| Source: TCGA |
| Type: Proapototic |
| TP53 is the most commonly mutated gene in human cancer. TP53 is a gene that encodes for the p53 tumor suppressor protein ; TP73 (Chr.1p36.33) and TP63 (Chr.3q28) genes that encode transcription factors p73 and p63, respectively, are TP53 homologous structures. p53 is a crucial tumor suppressor protein that plays a significant role in regulating the cell cycle, maintaining genomic stability, and preventing tumor formation. It is often referred to as the "guardian of the genome" due to its role in protecting cells from DNA damage and stress. TP53 gene, which encodes the p53 protein, is one of the most frequently mutated genes in human cancers. Overexpression of MDM2, an inhibitor of p53, can lead to decreased p53 activity even in the presence of wild-type p53. In some cancers, particularly those with mutant p53, there may be an overexpression of the p53 protein. Cancers with overexpression: Breast, lung, colorectal, overian, head and neck, Esophageal, bladder, pancreatic, and liver. |
| 2948- | PL, | The promising potential of piperlongumine as an emerging therapeutics for cancer |
| - | Review, | Var, | NA |
| 5161- | PLB, | Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells |
| - | in-vitro, | SCC, | SCC25 |
| 4968- | PSO, | Psoralidin: emerging biological activities of therapeutic benefits and its potential utility in cervical cancer |
| - | in-vitro, | Cerv, | NA |
| 5157- | PTL, | An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells |
| - | vitro+vivo, | AML, | NA |
| 1995- | PTL, | The protective effect of parthenolide in an in vitro model of Parkinson's disease through its regulation of nuclear factor-kappa B and oxidative stress |
| - | in-vitro, | Park, | SH-SY5Y |
| 1237- | PTS, | Pterostilbene induces cell apoptosis and inhibits lipogenesis in SKOV3 ovarian cancer cells by activation of AMPK-induced inhibition of Akt/mTOR signaling cascade |
| - | in-vitro, | Ovarian, | SKOV3 |
| 66- | QC, | Emerging impact of quercetin in the treatment of prostate cancer |
| - | Review, | Pca, | NA |
| 44- | QC, | Preclinical Colorectal Cancer Chemopreventive Efficacy and p53-Modulating Activity of 3′,4′,5′-Trimethoxyflavonol, a Quercetin Analog |
| - | in-vivo, | CRC, | HCT116 |
| 36- | QC, | Quercetin induces G2 phase arrest and apoptosis with the activation of p53 in an E6 expression-independent manner in HPV-positive human cervical cancer-derived cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | SiHa |
| 100- | QC, | Inhibition of Prostate Cancer Cell Colony Formation by the Flavonoid Quercetin Correlates with Modulation of Specific Regulatory Genes |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
| 910- | QC, | The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism |
| 923- | QC, | Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health |
| - | Review, | Var, | NA |
| 919- | QC, | Quercetin Regulates Sestrin 2-AMPK-mTOR Signaling Pathway and Induces Apoptosis via Increased Intracellular ROS in HCT116 Colon Cancer Cells |
| - | in-vitro, | CRC, | HCT116 |
| 894- | QC, | The antioxidant, rather than prooxidant, activities of quercetin on normal cells: quercetin protects mouse thymocytes from glucose oxidase-mediated apoptosis |
| - | in-vitro, | Nor, | NA |
| 4787- | QC, | Quercetin: A Phytochemical with Pro-Apoptotic Effects in Colon Cancer Cells |
| - | Review, | CRC, | NA |
| 3344- | QC, | Quercetin induced ROS production triggers mitochondrial cell death of human embryonic stem cells |
| - | in-vitro, | Nor, | hESC |
| 3354- | QC, | Quercetin: Its Main Pharmacological Activity and Potential Application in Clinical Medicine |
| - | Review, | Var, | NA |
| 3352- | QC, | A review of quercetin: Antioxidant and anticancer properties |
| - | Review, | Var, | NA |
| 3346- | QC, | Regulation of the Intracellular ROS Level Is Critical for the Antiproliferative Effect of Quercetin in the Hepatocellular Carcinoma Cell Line HepG2 |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | HUH7 |
| 3341- | QC, | Antioxidant Activities of Quercetin and Its Complexes for Medicinal Application |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA |
| 3368- | QC, | The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update |
| - | Review, | Var, | NA |
| 3369- | QC, | Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects |
| - | Review, | Pca, | NA |
| 1490- | RES, | Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues |
| - | Review, | Var, | NA |
| 2329- | RES, | Resveratrol induces apoptosis in human melanoma cell through negatively regulating Erk/PKM2/Bcl-2 axis |
| - | in-vitro, | Melanoma, | A375 |
| 3071- | RES, | Resveratrol and Its Anticancer Effects |
| - | Review, | Var, | NA |
| 3054- | RES, | Resveratrol induced reactive oxygen species and endoplasmic reticulum stress-mediated apoptosis, and cell cycle arrest in the A375SM malignant melanoma cell line |
| - | in-vitro, | Melanoma, | A375 |
| 3063- | RES, | Resveratrol: A Review of Pre-clinical Studies for Human Cancer Prevention |
| - | Review, | Var, | NA |
| 3061- | RES, | The Anticancer Effects of Resveratrol: Modulation of Transcription Factors |
| - | Review, | Var, | NA |
| 2981- | RES, | Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways |
| - | in-vitro, | Colon, | HT-29 | - | in-vitro, | Colon, | SW48 |
| 882- | RES, | Resveratrol: A Double-Edged Sword in Health Benefits |
| - | Review, | NA, | NA |
| 884- | RES, | PTS, | Resveratrol and Pterostilbene Exhibit Anticancer Properties Involving the Downregulation of HPV Oncoprotein E6 in Cervical Cancer Cells |
| - | in-vitro, | Cerv, | HeLa |
| 4668- | RES, | Resveratrol Impedes the Stemness, Epithelial-Mesenchymal Transition, and Metabolic Reprogramming of Cancer Stem Cells in Nasopharyngeal Carcinoma through p53 Activation |
| - | in-vitro, | NPC, | NA |
| 3005- | RosA, | Nanoformulated rosemary extract impact on oral cancer: in vitro study |
| - | in-vitro, | Laryn, | HEp2 |
| 4900- | Sal, | Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications |
| - | Review, | BC, | NA |
| 4903- | Sal, | Salinomycin: A new paradigm in cancer therapy |
| - | Review, | Var, | NA |
| - | in-vivo, | CRC, | Caco-2 | - | vitro+vivo, | CRC, | CX-1 |
| 323- | Sal, | AgNPs, | Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Ovarian, | A2780S |
| 4714- | Se, | SSE, | SeNPs, | Selenium in cancer management: exploring the therapeutic potential |
| - | Review, | Var, | NA |
| 4734- | SeNPs, | CPT-11, | Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles |
| - | in-vitro, | CRC, | HCT8 | - | in-vivo, | NA, | NA |
| 4453- | SeNPs, | Selenium Nanoparticles: Green Synthesis and Biomedical Application |
| - | Review, | NA, | NA |
| 1726- | SFN, | Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential |
| - | Review, | Var, | NA |
| 1722- | SFN, | Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems |
| - | Review, | Var, | NA |
| 1474- | SFN, | Sulforaphane induces p53‑deficient SW480 cell apoptosis via the ROS‑MAPK signaling pathway |
| - | in-vitro, | Colon, | SW480 |
| 1509- | SFN, | Combination therapy in combating cancer |
| - | Review, | NA, | NA |
| 3301- | SIL, | Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid |
| - | Review, | Var, | NA |
| 3296- | SIL, | Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway |
| - | in-vitro, | Oral, | Ca9-22 | - | in-vivo, | Oral, | YD10B |
| 3290- | SIL, | A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents |
| - | Analysis, | Var, | NA |
| 3288- | SIL, | Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations |
| - | Review, | Var, | NA |
| 978- | SIL, | A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment |
| - | Review, | NA, | NA |
| 2410- | SIL, | Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:236 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid